InvestorsHub Logo
Followers 20
Posts 2062
Boards Moderated 0
Alias Born 11/20/2016

Re: MOCKBA post# 5857

Thursday, 03/14/2019 3:45:36 PM

Thursday, March 14, 2019 3:45:36 PM

Post# of 6385
HOUSTON--(BUSINESS WIRE)-- Bio-Path Holdings, Inc. (BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced offering. In a registered direct offering, Bio-Path issued and sold 712,910 shares of its common stock for a price of $25.95 per share, for aggregate gross proceeds of approximately $18.5 million.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BPTH News